Management of Bipolar Disorder, ADD, and Anxiety

Concerns with Daily Lorazepam Use

• Regular use of benzodiazepines can lead to tolerance, addiction, depression, and cognitive impairment, according to the American Academy of Family Physicians 1
• Approximately 10% of patients treated with benzodiazepines experience paradoxical agitation, as reported by the American Academy of Family Physicians 1

Preferred Treatment Approach for This Complex Presentation

First Priority: Mood Stabilization

• The American Academy of Child and Adolescent Psychiatry recommends FDA-approved options for bipolar disorder, including lithium, valproate, aripiprazole, olanzapine, risperidone, quetiapine, and ziprasidone for acute mania in adults, and lithium, lamotrigine, and olanzapine for maintenance therapy 2, 3

Third Priority: Anxiety Management

• The American Academy of Family Physicians suggests valproate as a mood stabilizer with anti-anxiety properties, with an initial dosage of 125 mg twice daily, titrated to a therapeutic blood level of 40-90 mcg/mL 1
• The American Academy of Child and Adolescent Psychiatry recommends quetiapine, which has anxiolytic properties and is approved for bipolar disorder 2, 3
• The American Academy of Family Physicians recommends buspirone, a non-benzodiazepine anxiolytic, with an initial dosage of 5 mg twice daily, and a maximum of 20 mg three times daily 1

Psychotherapeutic Approaches

• The American Academy of Sleep Medicine suggests sleep hygiene therapy and stimulus control as helpful for insomnia components of anxiety 4

Monitoring and Precautions

• The American Academy of Child and Adolescent Psychiatry advises monitoring for mood switches if any antidepressant is used 2
• The American Academy of Family Physicians recommends using infrequent, low doses of benzodiazepines with short half-lives, and closely monitoring for tolerance, dependence, and cognitive effects 1

Management of Bipolar 2 Disorder with Increased Anxiety and Depression

Medication Considerations

• The patient's concerns about weight gain are valid as many medications for bipolar disorder can cause this side effect, with olanzapine having one of the highest risks for weight gain, according to the American Gastroenterological Association 5
• Lurasidone has demonstrated efficacy for bipolar depression with minimal weight gain and less sedation than other antipsychotics, as reported by the American Gastroenterological Association 5
• Bupropion is the only antidepressant consistently associated with weight loss rather than weight gain, according to the American Gastroenterological Association 5

Treatment Approach

• The American Academy of Sleep Medicine suggests that the sedative properties of quetiapine can be beneficial for anxiety and associated sleep disturbances 6
• The American Academy of Child and Adolescent Psychiatry recommends avoiding traditional antidepressant monotherapy as it may trigger manic episodes, and instead using it in combination with mood stabilizers 7
• The American Academy of Child and Adolescent Psychiatry also advises monitoring for treatment response and assessing for any emergence of manic/hypomanic symptoms, especially when adding an antidepressant like bupropion 7

Pharmacological Treatment of Bipolar Depression

Medication Efficacy and Safety

• The American Gastroenterological Association identifies lurasidone as having minimal weight gain and being among the most weight-neutral antipsychotics, with a weight change similar to placebo 8
• Cariprazine has a unique long-acting property due to its principal active metabolite, which has a half-life of 1-3 weeks and creates a "built-in" long-acting effect, but also means side effects may persist longer after discontinuation 8

Combination Therapy with Olanzapine and Valproate

Introduction to Combination Therapy

• The American Psychiatric Association recommends combination therapy with olanzapine and valproate for patients with bipolar disorder who have an inadequate response to monotherapy 9, 10

Special Populations

• In elderly patients, the initial dose of olanzapine should be reduced to 2.5-5 mg to minimize the risk of hypotension and excessive sedation 9
• The National Comprehensive Cancer Network recommends monitoring metabolic parameters, such as fasting glucose, lipid profile, and prolactin, at baseline and regularly during treatment with olanzapine 9, 10

Adverse Effects and Monitoring

• The combination of olanzapine and valproate can increase the risk of adverse effects, such as somnolence, dry mouth, weight gain, increased appetite, tremor, and slowed speech, which are more frequent with combination therapy than with monotherapy 9, 10, 11
• The FDA recommends avoiding excessive dopaminergic blockade when using olanzapine with metoclopramide, phenothiazines, or haloperidol 9, 10, 11

Warning and Precautions

• Olanzapine is associated with an increased risk of suicidal thoughts and behaviors in adolescents and young adults, and should be used with caution in these populations 9, 10
• The combination of olanzapine and valproate can increase the risk of serious skin reactions, such as DRESS syndrome, and patients should seek immediate medical attention if they experience fever, rash, and swollen lymph nodes 9, 10

Anxiety Management in Bipolar Disorder

Non-Pharmacological Interventions

• Cognitive behavioral therapy and psychoeducation should be routinely offered to patients with bipolar disorder as an adjunctive treatment for anxiety, as recommended by the American Psychological Association 12

Pharmacological Treatment

• The American Psychiatric Association recommends that buspirone can be considered as a third-line option for treating anxiety in patients with bipolar disorder, after mood stabilization is achieved with lithium, valproate, or atypical antipsychotics, with a recommended initial dose of 5 mg twice daily and a maximum dose of 20 mg three times daily 12

Treatment Approach for Bipolar Disorder

Medication Combination Principles

• The American Academy of Child and Adolescent Psychiatry supports a rational polypharmacy approach, treating multiple symptoms in the same patient, with a clear rationale for each medication in the combination, such as olanzapine for mood stabilization, buspirone for anxiety, and mirtazapine for insomnia 13
• Buspirone showed similar response and remission rates to bupropion when augmenting antidepressants for depression, though with slightly less reduction in depression severity, according to the American College of Physicians, as published in the Annals of Internal Medicine 14

Olanzapine for Anxiety in Bipolar Disorder

Atypical Antipsychotic Selection

• The American Academy of Family Physicians recommends avoiding typical antipsychotics, such as haloperidol, due to a 50% risk of tardive dyskinesia after 2 years in young patients, and instead using atypical antipsychotics for tolerability and efficacy 15

Medication Management

• The American Family Physician suggests that atypical antipsychotics, such as olanzapine, are superior to typical antipsychotics for tolerability and efficacy in patients with bipolar disorder and anxiety 15

Mirtazapine and Depakote Combination Therapy in Bipolar Disorder

Evidence for Combination Therapy

• The American Academy of Family Physicians recommends valproate therapeutic levels to be maintained at 40-90 mcg/mL to ensure adequate mood stabilization before adding any antidepressant, such as mirtazapine 16
• Mirtazapine at 7.5-30mg at bedtime is recognized as "potent and well tolerated" and "promotes sleep, appetite, and weight gain" by the American Family Physician 16

Monitoring and Dosing Considerations

• The American Family Physician suggests checking valproate levels, liver function tests, and complete blood count at baseline, then every 3-6 months when using mirtazapine and Depakote combination therapy 16
• Initial valproate dosing typically starts at 125mg twice daily and is titrated to therapeutic levels, as recommended by the American Family Physician 16

Alternative Therapies

• The American Family Physician recommends buspirone 5mg twice daily (maximum 20mg three times daily) as a non-benzodiazepine anxiolytic that can be added to mirtazapine and Depakote combination therapy 16

Mirtazapine Use in Bipolar Disorder with ADHD

ADHD Management Considerations

• Stimulant medications for ADHD should only be initiated after achieving stable mood control, as recommended by the American Academy of Child and Adolescent Psychiatry, with stimulants being contraindicated in patients with active psychotic disorder and must be used with great care in bipolar disorder 17, 18, 19
• Once mood symptoms are adequately controlled on a mood stabilizer regimen, stimulant medications may be helpful for comorbid ADHD, according to the American Academy of Child and Adolescent Psychiatry 17, 18